Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FELTON P ANDERSON

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1588655914
CMS profile
298851
Location
WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$2,998.65

106 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,593.60 102
Travel and Lodging $384.83 3
Education $20.22 1

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FELTON P ANDERSON

NPI 1588655914 · CMS profile ID 298851

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1588655914?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FELTON P ANDERSON, NPI 1588655914, CMS profile ID 298851. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1588655914?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). FELTON P ANDERSON, NPI 1588655914, CMS profile ID 298851. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1588655914?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
FELTON P ANDERSON, NPI 1588655914, CMS profile ID 298851, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 106 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1588655914?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

106 matching records · $2,998.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 106 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 106.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $12.9408/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229179360 CMS
Bayer Healthcare Pharmaceuticals Inc. $28.8108/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225446701 CMS
Amgen Inc. $5.6008/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227169605 CMS
Lilly USA, LLC $27.5408/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186584582 CMS
AstraZeneca Pharmaceuticals LP $14.5408/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207238842 CMS
SCPHARMACEUTICALS INC. $25.4508/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228194356 CMS
Bayer Healthcare Pharmaceuticals Inc. $30.4008/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225446699 CMS
GlaxoSmithKline, LLC. $21.3607/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190989913 CMS
Corcept Therapeutics $36.2507/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214222568 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.3907/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222792713 CMS
Corcept Therapeutics $27.1107/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214222564 CMS
Boston Scientific Corporation $24.6707/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181247538 CMS
SCPHARMACEUTICALS INC. $24.5707/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228191251 CMS
Corcept Therapeutics $25.9607/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214222562 CMS
E.R. Squibb & Sons, L.L.C. $25.5807/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184827275 CMS
Novartis Pharmaceuticals Corporation $35.3207/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200004765 CMS
Lilly USA, LLC $18.8906/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186562026 CMS
Novartis Pharmaceuticals Corporation $214.4306/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200004737 CMS
Novartis Pharmaceuticals Corporation $215.2106/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200004741 CMS
Novartis Pharmaceuticals Corporation $23.8206/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200004743 CMS
Novartis Pharmaceuticals Corporation $146.5806/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1200004745 CMS
Novartis Pharmaceuticals Corporation $133.9206/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200004739 CMS
SCPHARMACEUTICALS INC. $24.2906/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228188517 CMS
Verona Pharma, Inc. $20.8106/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233798875 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.5306/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1222792711 CMS
Amgen Inc. $5.6506/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227169601 CMS
Amgen Inc. $17.3506/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228468448 CMS
Lilly USA, LLC $27.6305/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186562028 CMS
GlaxoSmithKline, LLC. $27.6905/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1191404418 CMS
Lilly USA, LLC $23.8605/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186607016 CMS
Bayer Healthcare Pharmaceuticals Inc. $14.1605/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225446697 CMS
PFIZER INC. $23.0705/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231290644 CMS
SCPHARMACEUTICALS INC. $31.9205/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228185352 CMS
Amgen Inc. $6.6405/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227169595 CMS
Verona Pharma, Inc. $19.9605/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233798965 CMS
E.R. Squibb & Sons, L.L.C. $24.7605/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184827423 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $24.1605/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231882533 CMS
Merck Sharp & Dohme LLC $18.4304/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238176599 CMS
E.R. Squibb & Sons, L.L.C. $15.7004/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1184827409 CMS
PFIZER INC. $0.6104/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228845053 CMS
PFIZER INC. $22.1704/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228892919 CMS
AstraZeneca Pharmaceuticals LP $19.6004/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206387637 CMS
AstraZeneca Pharmaceuticals LP $28.1403/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206866616 CMS
SCPHARMACEUTICALS INC. $34.9103/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228180838 CMS
Bayer Healthcare Pharmaceuticals Inc. $26.7703/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1225446695 CMS
Corcept Therapeutics $28.0603/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1214222524 CMS
Amgen Inc. $9.6203/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227169603 CMS
GlaxoSmithKline, LLC. $30.6303/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1190541372 CMS
Merck Sharp & Dohme LLC $22.8903/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238268206 CMS
AstraZeneca Pharmaceuticals LP $19.7002/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206651121 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $4,156.33 181
PY2020 $2,678.85 156
PY2021 $2,039.81 109
PY2022 $2,497.04 98
PY2023 $3,110.27 100
PY2024 $5,321.97 87
PY2025 $2,998.65 106

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $4,288.93 10
PY2025 Principal investigator $911,099.41 14
PY2024 Recipient $146,176.93 4
PY2024 Principal investigator $463,282.74 10
PY2023 Principal investigator $477,600.70 29
PY2022 Principal investigator $324,714.27 7
PY2021 Principal investigator $122,092.15 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Regeneron Pharmaceuticals, Inc. $339.78 12/06/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184115073
Recipient Regeneron Pharmaceuticals, Inc. $607.26 12/06/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184115075
Recipient Regeneron Pharmaceuticals, Inc. $89.89 12/06/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184115077
Recipient Regeneron Pharmaceuticals, Inc. $41.49 12/06/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184115079
Recipient Regeneron Pharmaceuticals, Inc. $110.63 12/06/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184115081
Recipient Regeneron Pharmaceuticals, Inc. $41.49 12/06/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184115083
Recipient Regeneron Pharmaceuticals, Inc. $88.50 12/06/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184115085
Recipient Regeneron Pharmaceuticals, Inc. $131.30 12/05/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184115071
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,241.74 11/12/2025 Non-covered Recipient Entity
ANDERSON MEDICAL RESEARCH
A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a) No dispute reported 06/30/2026 1190311227
Recipient Regeneron Pharmaceuticals, Inc. $426.97 11/11/2025 Covered Recipient Physician A Phase 2, Randomized, Multicenter, Open-label, Blinded-endpoint Study to Evaluate the Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against FXI, Versus Apixaban in Participants With Atrial Fibrillation (ROXI-ATLAS) No dispute reported 06/30/2026 1184115069
Principal investigator 1 Eli Lilly and Company $837.13 09/26/2025 Non-covered Recipient Entity
COLUMBUS CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187882274
Principal investigator 1 Eli Lilly and Company $4,645.16 08/26/2025 Non-covered Recipient Entity
ANDERSON MEDICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187874469
Principal investigator 1 Novartis Pharmaceuticals Corporation $106,057.94 04/28/2025 Non-covered Recipient Entity
ANDERSON MEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Atherosclerotic Cardiovascular Disease (ASCVD), and Elevated LDL-C No dispute reported 06/30/2026 1190311241
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,597.44 04/16/2025 Non-covered Recipient Entity
ANDERSON MEDICAL RESEARCH
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open-Label Pelacarsen in Participants With Elevated Lp(a) and Established ASCVD No dispute reported 06/30/2026 1190311243
Principal investigator 1 Novartis Pharmaceuticals Corporation $84,309.65 03/12/2025 Non-covered Recipient Entity
ANDERSON MEDICAL RESEARCH
A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients No dispute reported 06/30/2026 1190311235
Principal investigator 1 Novartis Pharmaceuticals Corporation $44,319.31 02/04/2025 Non-covered Recipient Entity
ANDERSON MEDICAL RESEARCH
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardi No dispute reported 06/30/2026 1190311239
Principal investigator 1 Novartis Pharmaceuticals Corporation $153,768.19 01/30/2025 Non-covered Recipient Entity
ANDERSON MEDICAL RESEARCH
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190311229
Principal investigator 1 Novartis Pharmaceuticals Corporation $12,829.28 01/30/2025 Non-covered Recipient Entity
ANDERSON MEDICAL RESEARCH
A multi-center, randomized, double-blind, placebo-controlled, parallel-group Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diag No dispute reported 06/30/2026 1190311233
Recipient Eli Lilly and Company $2,411.62 01/27/2025 Covered Recipient Physician A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187872929
Principal investigator 1 Novartis Pharmaceuticals Corporation $93,642.28 01/27/2025 Non-covered Recipient Entity
ANDERSON MEDICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190311231
Principal investigator 1 Eli Lilly and Company $55,100.00 01/21/2025 Non-covered Recipient Entity
ANDERSON MEDICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187874707
Principal investigator 1 Novartis Pharmaceuticals Corporation $50,732.58 01/15/2025 Non-covered Recipient Entity
ANDERSON MEDICAL RESEARCH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190311237
Principal investigator 1 Eli Lilly and Company $278,803.00 01/07/2025 Non-covered Recipient Entity
ANDERSON MEDICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187874351
Principal investigator 1 Novartis Pharmaceuticals Corporation $9,215.71 01/01/2025 Non-covered Recipient Entity
ANDERSON MEDICAL RESEARCH
A Multi-center, Randomized, Double-blind, Parallel-group, 20-week Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of XXB750 in Patients With Resistant Hypertension No dispute reported 06/30/2026 1190311245